post-marketing surveillance raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-07-21 and is reviewed periodically as new material appears.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
=== Laser === Argon laser trabeculoplasty (ALT) may be used to treat open-angle glaucoma, but this is a temporary solution, not a cure. A 50-μm argon laser spot is aimed at the trabecular meshwork to stimulate the opening of the mesh to allow more outflow of aqueous fluid. Usually, half of the angle is treated at a time. Traditional laser trabeculoplasty uses a thermal argon laser in an argon laser trabeculoplasty procedure. Nd:YAG laser peripheral iridotomy (LPI) may be used in patients susceptible to or affected by angle closure glaucoma or pigment dispersion syndrome. During laser iridotomy, laser energy is used to make a small, full-thickness opening in the iris to equalize the pressure between the front and back of the iris, thus correcting any abnormal bulging of the iris. In people with narrow angles, this can uncover the trabecular meshwork. In some cases of intermittent or short-term angle closure, this may lower the eye pressure. Laser iridotomy reduces the risk of developing an attack of acute angle closure. In most cases, it also reduces the risk of developing chronic angle closure or of adhesions of the iris to the trabecular meshwork. Computational fluid dynamics (CFD) simulations have shown that an optimal iridotomy size to relieve the pressure differential between the anterior and posterior side of the iris is around 0.1 mm to 0.2 mm. This coincides with clinical practice of LPI where an iridotomy size of 150 to 200 microns is commonly used. However, larger iridotomy sizes are sometimes necessary.
The thus-produced 249Bk has a long half-life of 330 days and thus can capture another neutron. However, the product, 250Bk, again has a relatively short half-life of 3.212 hours and thus does not yield any heavier berkelium isotopes. It instead decays to the californium isotope 250Cf:
== History == Dalbavancin has undergone a phase-III clinical trial for adults with complicated skin infections, but in December 2007, the US Food and Drug Administration (FDA) said more data were needed before approval. Pfizer withdrew its marketing applications to conduct another phase-III clinical trial in September 2008. Durata Therapeutics acquired the rights to dalbavancin in December 2009, and has initiated two new phase-III clinical trials for treatment of ABSSSIs. Preliminary results in 2012 were promising. About 1,289 adults with ABSSSI were given dalbavancin or vancomycin randomly, and dalbavancin was found to exhibit efficacy comparable to vancomycin. In May 2014, dalbavancin was approved for medical use in the United States for ABSSSIs, including MRSA and Streptococcus pyogenes infections.
=== Mass campaigns and high office === Liu retained his political standing through active participation in the state's major mass campaigns. During the land reform movement, Liu announced at a conference that: "I once used to be a big landlord, but now I will unconditionally and unreservedly distribute the land to the peasants." According to Guangming Daily, this statement won him enthusiastic applause from the attendance. In 1955, during the Sufan campaign, Liu called for "greater vigilance" against "counterrevolutionaries". In 1956, he spoke in Chengdu on the occasion of the 90th anniversary of Sun Yat-sen's birth, publicly praising all of the Communist Party's political positions. Politically, he was elected to the 3rd Central Committee of the Revolutionary Committee of the Chinese Kuomintang in 1954, serving until his death. He also served as Minister of Forestry from 1959 to 1967. In this capacity, he made reports on the state of forestry in China and carried out inspections in Jiangxi province as well as other regions. At the second National People's Congress in 1960 during the Great Leap Forward, Liu Wenhui declared that the country was in the midst of a "forestry revolution." Liu Wenhui escaped persecution during the Cultural Revolution due to Zhou Enlai's protection, but he was unable to stop his older brother, Liu Wencai (who had died in 1949), from becoming demonized by state media and remembered in the popular imagination as a tyrannical and corrupt landlord.
Sources: en.wikipedia.org
Like all catalysts, enzymes do not affect the overall equilibrium of a reaction and are regenerated at the end of each cycle. What distinguishes them is their high specificity, determined by their unique three-dimensional structure, and their sensitivity to factors such as temperature and pH. Enzyme activity can be enhanced by activators or diminished by inhibitors, many of which serve as drugs or poisons. Outside optimal conditions, enzymes may lose their structure through denaturation, leading to loss of function. Enzymes have widespread practical applications. In industry, they are used to catalyze the production of antibiotics and other complex molecules. In everyday life, enzymes in biological washing powders break down protein, starch, and fat stains, enhancing cleaning performance. Papain and other proteolytic enzymes are used in meat tenderizers to hydrolyze proteins, improving texture and digestibility. Their specificity and efficiency make enzymes indispensable in both biological systems and commercial processes.
=== Psychosocial === Peyronie's disease can also have psychological effects. While most men will continue to be able to have sexual relations, they are likely to experience some degree of erectile dysfunction. It is not uncommon to exhibit depression or withdrawal from their sexual partners. In one study, 81% of men diagnosed with Peyronie's disease reported emotional difficulties. 48% reported clinically meaningful depression. Of those, 26% experienced moderate depression, while 21% experienced severe depression. 54% reported relationship problems due to Peyronie's disease. Peyronie's disease can cause patients to feel socially isolated and stigmatized. Physicians may be unaware of the psychological effects suffered by patients and their partners. Many men with Peyronie's disease avoid intimacy and isolate themselves as they cope with anger, depression, fear of rejection, and decreased self‐worth.
These ideas received wide and influential backing, when James Cook set off to circumnavigate the world (1768–1771) in HM Bark Endeavour, malt and wort were top of the list of the remedies he was ordered to investigate. The others were beer, sauerkraut (a good source of vitamin C), and Lind's 'rob'. The list did not include lemons. Cook did not lose a single man to scurvy, and his report came down in favor of malt and wort. The reason for the health of his crews on this and other voyages was Cook's regime of shipboard cleanliness, enforced by strict discipline, and frequent replenishment of fresh food and greenstuffs. Another beneficial rule implemented by Cook was his prohibition of the consumption of salt fat skimmed from the ship's copper boiling pans, then a common practice elsewhere in the Navy. In contact with air, the copper formed compounds that prevented the absorption of vitamins by the intestines. The first major long-distance expedition that experienced virtually no scurvy was that of the Spanish naval officer Alessandro Malaspina, 1789–1794. Malaspina's medical officer, Pedro González, was convinced that fresh oranges and lemons were essential for preventing scurvy. Only one outbreak occurred, during a 56-day trip across the open sea. Five sailors came down with symptoms, one seriously. After three days at Guam, all five were healthy again. Spain's large empire and many ports of call made it easier to acquire fresh fruit.
=== Cardiovascular === Although cardiovascular involvement depends significantly on the diagnosed subtype of EDS, several co-morbidities and symptoms are closely linked to the disorder as a whole. Some studies suggest that structural abnormalities are not the root cause of the vast majority of cardiac symptoms, but rather, dysautonomia is the primary culprit. Associated symptoms can include, but are not limited to, palpitations, near-syncope and syncope, heat intolerance, and difficulty managing blood pressure and heart rate. One study published in 2013 found that patients with EDS were more likely to also be diagnosed with postural orthostatic tachycardia syndrome, more commonly known as POTS. Weak connective tissues in the heart can cause problems with valve structure and function. Mitral valve prolapse and regurgitation and aortic root dilation are found more commonly in EDS patients and others with similar connective tissue disorders. In some cases, EDS manifests within the vasculature as well. Major artery aneurysms and dissections are sometimes seen as a result of faulty structural integrity.
Per Mendeleev's nomenclature for unnamed and undiscovered elements, flerovium is sometimes called eka-lead. In 1979, IUPAC published recommendations according to which the element was to be called ununquadium (symbol Uuq), a systematic element name as a placeholder, until the discovery of the element is confirmed and a permanent name is decided on. Most scientists in the field called it "element 114", with the symbol of E114, (114) or 114. Per IUPAC recommendations, the discoverer(s) of a new element has the right to suggest a name. After IUPAC recognized the discovery of flerovium and livermorium on 1 June 2011, IUPAC asked the discovery team at JINR to suggest permanent names for the two elements. The Dubna team chose the name flerovium (symbol Fl), after Russia's Flerov Laboratory of Nuclear Reactions (FLNR), named after Soviet physicist Georgy Flyorov (also spelled Flerov); earlier reports claim the element name was directly proposed to honour Flyorov. In accordance with the proposal received from the discoverers, IUPAC officially named flerovium after Flerov Laboratory of Nuclear Reactions, not after Flyorov himself. Flyorov is known for writing to Joseph Stalin in April 1942 and pointing out the silence in scientific journals in the field of nuclear fission in the United States, Great Britain, and Germany. Flyorov deduced that this research must have become classified information in those countries. Flyorov's work and urgings led to the development of the USSR's own atomic bomb project.
Sources: en.wikipedia.org
The advent of insulin analogs and continued use of NPH insulin led to the discontinuation of ultralente insulin products in the mid-2000s, and FDA approval to be marketed in the US was withdrawn by 2011.
Substituted phenethylamines are a chemical class of organic compounds based upon the phenethylamine structure; the class is composed of all the derivative compounds of phenethylamine which can be formed by replacing, or substituting, one or more hydrogen atoms in the phenethylamine core structure with substituents. Many substituted phenethylamines are psychoactive drugs, which belong to a variety of different drug classes, including central nervous system stimulants (e.g., amphetamine), hallucinogens (e.g., 2,5-dimethoxy-4-methylamphetamine), entactogens (e.g., 3,4-methylenedioxyamphetamine), appetite suppressants (e.g. phentermine), nasal decongestants and bronchodilators (e.g., pseudoephedrine), antidepressants (e.g. bupropion), antiparkinson agents (e.g., selegiline), and vasopressors (e.g., ephedrine), among others. Many of these psychoactive compounds exert their pharmacological effects primarily by modulating monoamine neurotransmitter systems; however, there is no mechanism of action or biological target that is common to all members of this subclass. Numerous endogenous compounds—including hormones, monoamine neurotransmitters, and many trace amines (e.g., dopamine, norepinephrine, adrenaline, tyramine, and others)—are substituted phenethylamines. Dopamine is simply phenethylamine with a hydroxyl group attached to the 3 and 4 position of the benzene ring. Several notable recreational drugs, such as MDMA (ecstasy), methamphetamine, and cathinones, are also members of the class. All of the substituted amphetamines are phenethylamines, as well.
==== Plasma levels ==== Plasma potassium is normally kept at 3.5 to 5.5 millimoles (mmol) [or milliequivalents (mEq)] per liter by multiple mechanisms. Even narrower ranges are required to reduce mortality for patients with acute myocardial infarction. An average meal of 40–50 mmol presents the body with more potassium than is present in all plasma (20–25 mmol). Renal and extrarenal mechanisms external homeostasis mechanisms limit the rise in plasma potassium to less than 10%. Hypokalemia, a deficiency of potassium in the plasma, can be fatal if severe. Common causes are increased gastrointestinal loss (vomiting, diarrhea), and increased renal loss (diuresis). Deficiency symptoms include muscle weakness, paralytic ileus, ECG abnormalities, decreased reflex response; and in severe cases, respiratory paralysis, alkalosis, and cardiac arrhythmia.
Allyn Taylor International Prize in Medicine for Diabetes, Toronto, Canada (2002) Manpei Suzuki International Prize for Top Diabetes Researcher Worldwide (Inaugural Recipient), Tokyo, Japan (2009) Hans Falk Memorial Lecture, National Institute of Environmental Health Science (2009) Presidential Lecture, Memorial Sloan Kettering Cancer Institute, New York (2010) Alpha Omega Alpha Visiting Professor, Columbia University Medical School, New York, NY (2010) Frontiers in Science Award, American Association of Clinical Endocrinologists (2010) Cockrell Foundation Award in Basic and Clinical Research, Houston, TX (2010) Distinguished Leader in Insulin Resistance, World Congress of Insulin Resistance in Diabetes and Cardiovascular Disease, Los Angeles, CA (2010) David Murdock Dole Honorary Lecture, Mayo Clinic-Karolinska, Nobel Forum, Stockholm, Sweden (2011) Wallace H. Coulter Award, American Association of Clinical Chemistry (2013) Helmholtz Diabetes Research Lifetime Achievement Award, Munich, Germany (2013) Honorary Adjunct Member, Max Planck Institute, Cologne, Germany (2014) Ipsen Foundation Prize in Endocrine Regulation (2015) Harold Hamm Prize in Diabetes (2015) Wolf Prize in Medicine, Jerusalem, Israel (2016)
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.